An observational study to describe the population of patients treated with extended adjuvant neratinib.
An observational study to describe the population of patients treated with extended adjuvant neratinib.
Retrospective observational study of adult patients with early-stage HER-2 positive breast cancer, treated with neratinib as extended adjuvant therapy in the context of the European Early Access Program.
Brief summary
HER2+ breast cancer is a subtype of breast cancer which represents approximately 15% to 25% of breast cancer worldwide.
In patients with early-stage HER2+ breast cancer, a pivotal clinical study demonstrated that the use neratinib (Nerlynx®), following (neo)adjuvant trastuzumab based therapy, improves clinical outcomes of patients.
In this context, the purpose of this observational retrospective study is to describe the population of patients in Europe who were treated with extended adjuvant neratinib after having received a trastuzumab based therapy*.
*Trastuzumab based therapy = treatment with trastuzumab combined with chemotherapy, with or without pertuzumab, or treatment with trastuzumab emtansine and being part of the reference treatment for adjuvant (= post surgery) therapy of HER2+ breast cancer.
Contact Us
Need more information, click on the button to have access to the contact form.
Access to Lay Protocol Synopsis
Un résumé du protocole rédigé en termes simples et décrivant les objectifs de l’étude vous est proposé.